Immune cell markers in adults with bipolar disorder compared with healthy people
Compares markers on CD8+ T cells in blood of people with and without bipolar disorder.
Plain-language title generated from the registry record
Registry title: Chemokine Receptors on CD8+ T Cells in Patients With Bipolar Disorder
Key facts
- Where
- Catania, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 25 to 35 with Bipolar I or II disorder who have never taken psychiatric drugs or have stopped them for 6 months. It also enrols healthy controls.
- Age
- 25 to 35 years
- Sex
- Men and women. Women must be in the mid-luteal phase of the menstrual cycle.
- Disease stage
- Bipolar I or Bipolar II Disorder; first diagnosis, depressive or manic/hypomanic phase may be explored.
- Earlier treatment
- No psychiatric medicine ever (drug-naive), or none for at least 6 months (drug-free).
Main reasons for not taking part
- Current treatment with corticosteroids, immunosuppressive agents, antibiotics, or hormone replacement therapy
- Autoimmune disease or other clinically significant medical conditions
- Other relevant psychiatric conditions
- Psychiatric medicine taken now or stopped less than 6 months before joining
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 35 years old?
Source: NCT07785167, who can take part
Where in Italy
- Psychiatry Unit, Policlinico "G.Rodolico" Hospital, Via Santa Sofia 78Catania, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Catania
- Trial code
- NCT07785167
- Record updated
- 25 August 2026
- Original description
This observational study investigates the expression profile of chemokine receptors and adhesion molecules in CD8+ T lymphocytes from individuals with Bipolar Disorder compared with healthy controls. The study focuses on CCR5 and CXCR3, which are involved in CD8+ T-cell migration toward the central nervous system, as well as the adhesion-related molecules PSGL-1, VLA-4, and LFA-1. Participants with Bipolar I or Bipolar II Disorder will be drug-naive or drug-free for at least 6 months and will be compared with healthy controls. Differences in molecular expression will also be explored according to the current mood episode, including depressive and manic/hypomanic phases. Gene expression will be assessed by real-time PCR in purified CD8+ T lymphocytes obtained from peripheral blood samples.Read full original descriptionShow less
Characterization of Chemokine Receptor Expression in CD8+ T Lymphocytes in Bipolar Disorder
This observational study investigates the expression profile of chemokine receptors and adhesion molecules in CD8+ T lymphocytes from individuals with Bipolar Disorder compared with healthy controls. The study focuses on CCR5 and CXCR3, which are involved in CD8+ T-cell migration toward the central nervous system, as well as the adhesion-related molecules PSGL-1, VLA-4, and LFA-1. Participants with Bipolar I or Bipolar II Disorder will be drug-naive or drug-free for at least 6 months and will be compared with healthy controls. Differences in molecular expression will also be explored according to the current mood episode, including depressive and manic/hypomanic phases. Gene expression will be assessed by real-time PCR in purified CD8+ T lymphocytes obtained from peripheral blood samples.
Inclusion: Participants with Bipolar Disorder:; Age 25 to 35 years; Male or female; female participants must be in the mid-luteal phase of the menstrual cycle; Clinical presentation consistent with a diagnosis of Bipolar I Disorder or Bipolar II Disorder; First diagnosis of Bipolar Disorder with no previous psychopharmacological treatment (drug-naive), or absence of psychopharmacological treatment for at least 6 months (drug-free); Ability and willingness to provide written informed consent; Healthy Controls Group:; Age 25 to 35 years; Male or female; female participants must be in the mid-luteal phase of the menstrual cycle; No current treatment with psychotropic medications; No clinical or symptomatic evidence supporting a diagnosis of Bipolar I Disorder or Bipolar II Disorder; Hamilton Depression Rating Scale (HAM-D) score <8; Mania Rating Scale (MRS) score <11; No major stressful life events during the previous 6 months, such as bereavement, traumatic events, or divorce; Ability and willingness to provide written informed consent.
Exclusion: Current treatment with corticosteroids, immunosuppressive agents, antibiotics, or hormone replacement therapy; Current psychopharmacological treatment or psychopharmacological treatment discontinued less than 6 months before enrollment; Relevant current medical comorbidities, including autoimmune diseases or other clinically significant internal medicine conditions; Relevant psychiatric comorbidities.